Tisdag 26 November | 09:49:59 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-26 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-14 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-04-05 - Extra Bolagsstämma 2024
2024-02-28 - Bokslutskommuniké 2023
2023-12-20 - Extra Bolagsstämma 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-07-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Årsstämma
2023-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-16 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 - Årsstämma
2022-05-13 - Kvartalsrapport 2022-Q1
2022-04-08 - Extra Bolagsstämma 2022
2022-02-16 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-16 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-06-05 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-12-19 - Extra Bolagsstämma 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-13 - Kvartalsrapport 2019-Q2
2019-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 - Årsstämma
2019-05-08 - Kvartalsrapport 2019-Q1
2019-02-12 - Bokslutskommuniké 2018
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-07-25 - Extra Bolagsstämma 2018
2018-05-09 - X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 - Årsstämma
2018-05-08 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-21 - Kvartalsrapport 2017-Q3
2017-08-22 - Kvartalsrapport 2017-Q2
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-04-22 - Bokslutskommuniké 2016
2016-11-11 - Kvartalsrapport 2016-Q3
2016-09-21 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2023-10-29 19:55:00

The board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") has today, based on the authorisation from the annual general meeting held on 29 May 2023, resolved to approve a directed share issue of 10,850,000 series B shares to the strategically important investors Mountain High Trust and Ran Goldstein. The shares in the directed share issue are issued at a subscription price of SEK 0.27 per share, which is a 4,2% premium to the 30-day VWAP. Through the directed share issue the Company receives proceeds of SEK 2,929,500, before transaction costs.

The Simris Group board of directors has today, based upon the authorisation from the annual general meeting held on 29 May 2023, resolved to approve a directed share issue of 10,850,000 series B shares to the strategically important investors Mountain High Trust and Ran Goldstein. The shares in the directed share issue are issued at a subscription price of SEK 0.27 per share, which exceeds the volume-weighted average price during the last 30 trading days by approximately 4,2%. Through this directed share issue, the Company receives proceeds of SEK 2,929,500 before transaction costs. The subscription price has been determined through negotiations at arm's length.

The proceeds from this directed share issue will provide increased financial flexibility and freedom of action for the Company in order to drive the business forward. The directed share issue also enables the board to implement other financing solutions in the future.

Simris Group Chairman, Steven Schapera commented: "It is most reassuring that Mountain High Trust has sought to increase their recent commitment made just over a month ago, and also to be joined by Ran Goldstein, another strategic investor with an interest in the longer-term future of Simris. The fact that they have invested at a small premium to the 30-day VWAP is a robust vote of confidence."

The recent, fully underwritten, Rights Issue was approximately 58.9 percent subscribed for with and without the support of subscription rights and completed on 18th August 2023. At the same time the Company ran a strategic directed share issue whereby the participants in the directed issue also acted as underwriters of the Rights Issue and whereby any funds not called upon to underwrite the Rights Issue, would roll over into a directed issue. This resulted in a shortfall of approximately SEK 10,0m versus the target for the total capital raising.
In determining how best to fill all or part of this shortfall, the board of directors has carefully considered all available fundraising options.

Based upon an approach from two strategic investors, namely Mountain High Trust and Ran Goldstein, it was agreed to accept their offer to subscribe via a directed share issue. This decision was made against the background of the size of the shortfall not justifying for a new Rights Issue, the lack of participation in the recent Rights Issue despite its discounted offer price, decreasing access to risk capital investors, the prevailing sentiment in the market, and the share price volatility that has been observed for smaller growth companies in general and the Company in particular.

The board also considered that the costs of a Rights Issue would be disproportionately high in relation to the capital raised. In addition, a Rights Issue would probably have been made at a lower subscription price, given the discount levels that existed in Rights Issues carried out in growth companies on the market recently. In summary, the board of directors assessed that the choice to carry out a top-up directed share issue to strategic investors ensures that a larger proportion of the raised proceeds will be raised without delay and at significantly lower cost, thereby benefitting the Company and its shareholders compared with a Rights Issue.

The board of the Company has determined that the subscription price is market-based and correctly reflects their assessment of market conditions and demand. The subscription price has been negotiated at arm's length and the board of directors has been able to safeguard the interest of shareholders by carrying out this directed issue without the issue discounts common in the current market. This issue has been carried out at an issue premium to the 30-day VWAP, which are far better issue conditions for the Company than what is generally established in transactions of the same kind or in Rights Issues. The board of directors therefore assesses that the subscription price is favorable for the Company's shareholders and that it is in the Company's and the shareholders interest to carry out the directed share issue at the established subscription price and that the subscription price is clearly within the framework of what should be considered marketable at present, given the subscription premium.

The directed share issue entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the Company. Through the directed share issue, the number of shares and votes in the Company increases by 10,850,000 from 332,050,556 to 342,900,556. The share capital increases by SEK 942,597.30 from SEK 28,847,001.67 to SEK 29,789,598.97.